Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality(TM) (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache

Lilly also plans to submit a supplemental Biologics License Application (sBLA) to the FDA for Emgality for the preventive treatment of episodic cluster headache by the end of the year, reflecting its commitment to disabling headache disorders INDIANAPOL... Biopharmaceuticals, Neurology, FDA Eli Lilly, lasmiditan, migraine, Emgality, galcanezumab-gnlm
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news